Tiziana Life Sciences plc ("Tiziana" or the "Company") - Gabriele Cerrone, Chairman of Tiziana Life Sciences, to give interview on Bloomberg Television US at 1:20 PM ET Today
Tiziana Life Sciences (NASDAQ: TLSA; LSE: TILS) announces that Chairman Gabriele Cerrone will appear on Bloomberg Television on March 29, 2021, at 1:20 PM EST.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Tiziana Life Sciences (NASDAQ: TLSA; LSE: TILS) announces that Chairman Gabriele Cerrone will appear on Bloomberg Television on March 29, 2021, at 1:20 PM EST. This interview will be featured on the Bloomberg Surveillance Show. Tiziana Life Sciences is a UK biotechnology firm concentrating on therapeutics for oncology and immunology, with ongoing developments such as Milciclib and Foralumab, which is a fully human anti-CD3 monoclonal antibody. The company is also advancing an anti-IL6R monoclonal antibody aimed at treating COVID-19 patients.
Positive
- Chairman Gabriele Cerrone's interview on Bloomberg could enhance visibility and investor interest.
- Ongoing development of Foralumab, a unique fully human anti-CD3 monoclonal antibody, which may have broad applications.
- Focus on anti-IL6R monoclonal antibody indicates proactive steps in addressing COVID-19.
Negative
- None.
Details
News Market Reaction – TLSA
The recorded move for TLSA in the trading session of this news was -1.12%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK and LONDON, March 29, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences. (NASDAQ: TLSA; LSE: TILS), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, announces that the Chairman and founder, Gabriele Cerrone, will give an interview on Bloomberg Television on Monday, 29 March 2021 at 1.20 p.m. US Eastern Standard Time (6.20 p.m. London) as part of the Bloomberg Surveillance Show.
About Tiziana Life Sciences
Tiziana Life Sciences plc is a UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology. In addition to Milciclib, the Company is also developing Foralumab for liver diseases. Foralumab is the only fully human anti-CD3 monoclonal antibody in clinical development in the world. This Phase 2 compound has potential application in a wide range of autoimmune and inflammatory diseases, such as non-alcoholic steatohepatitis (NASH), ulcerative colitis, multiple sclerosis, type-1 diabetes (T1D), Crohn's disease, psoriasis and rheumatoid arthritis, where modulation of a T-cell response is desirable. The company is accelerating development of anti-Interleukin 6 receptor (IL6R) mAb, a fully human monoclonal antibody for treatment of IL6-induced inflammation, especially for treatment of COVID-19 patients.
For further enquiries:
United Kingdom Investors:
Tiziana Life Sciences plc (TLSA)
Gabriele Cerrone, Chairman and founder
+44 (0)20 7495 2379
U.S. Investor Relations Contact:
RedChip Companies, Inc.
Dave Gentry1-800 RED-CHIP (733-2447)
Or 407-491-4498
407-491-4498
dave@redchip.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.